Chen WC, Baal UH, Baal JD, et al. - Whether stereotactic radiosurgery (SRS) affords a safe as well as effective treatment option for brainstem metastasis (BSM), was investigated via this systematic review and meta-analysis. Also, this approach was compared with SRS or targeted therapy for nonbrainstem brain metastasis (BM). Experts analyzed 32 studies comprising 1446 patients, identified from Pubmed/MEDLINE and Embase. Findings revealed links with high local control (86%), high therapeutic ratio of symptom relief and tumor response (50%-60%) relative to targeted therapy (17%-56%), rare significant toxic effects (2.4%), and rare death from BSM progression (2.7%). Results demonstrated not only the effectiveness and safety of SRS for BSM but also it was comparable to SRS for nonbrainstem BM, implying BSM cases should be eligible for clinical trials of SRS. In this study, rarely death from BSM progression occurred in patients who received SRS for BSM, rather these patients often had symptomatic improvement. In view of apparent safety as well as efficacy of SRS for BSM in the context of acute morbidity or death from BSM progression, consideration of SRS at the time of enrollment on emerging trials of targeted therapy for BM is advised to be considered.